Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters

Journal of Molecular and Cellular Cardiology

Volumn 37, Issue 3, 2004, Pages 767-774

  Masunaga, Rumi ^a   Nagasaka, Akio ^a   Sawai, Yoshikuni ^a   Hayakawa, Nobuki ^a   Nakai, Akira ^a   Hotta, Keiko ^a   Kato, Yasuchika ^a   Hishida, Hitoshi ^a   Takahashi, Hisahide ^a   Naka, Michiko ^b   Shimada, Yasuhito ^b   Tanaka, Toshio ^b   Hidaka, Hiroyoshi ^c   Itoh, Mitsuyasu ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c D Western Therapeutics Institute   (Japan)

Author keywords

Calmodulin; Cyclic nucleotide phosphodiesterase; Myopathic hamster

Indexed keywords

CALMODULIN; CALMODULIN INHIBITOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIETHYLAMINOETHYL CELLULOSE; ISOENZYME; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL FRACTIONATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; HAMSTER; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AGE FACTORS; ANIMALS; CALMODULIN; CARDIOMYOPATHIES; CRICETINAE; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; ISOENZYMES; MYOCARDIAL CONTRACTION; MYOCARDIUM;

ANIMALIA; CRICETINAE;

EID: 4444243523     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.06.013     Document Type: Article

References (54)

1. Sutherland E.W., Roll T.W. Fractionation and characterization of a cyclic adenosine ribonucleotide formed by tissue particles. J Biol Chem. 243:1958;1077-1091
2. Cheung W.Y. Cyclic 3′,5′-nucleotide phosphodiesterase. Evidence for and properties of a protein activator. J Biol Chem. 246:1971;2859-2869
3. 2+. Proc Natl Acad Sci USA. 70:1973;3526-3530
4. 2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature. 345:1990;158-161
5. Movsesian M.A. cAMP-mediated signal transduction and sarcoplasmic reticulum function in heart failure. Ann NY Acad Sci. 853:1998;231-239
6. Levey G.S., Epstein S.E. Myocardial adenyl cyclase: activation by thyroid hormones and evidence for two adenyl cyclase systems. J Clin Invest. 48:1969;1663-1669
7. Brechler V., Pavoine C., Hanf R., Garbarz E., Fischmeister R., Pecker F. Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phosphodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein. J Biol Chem. 267:1992;15496-15501
8. Beavo J.A., Reifsenyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of elective inhibitors. Trend Pharmacol Science. 11:1990;150-155
9. Conti M., Jin S.L., Monaco L., Repaske D.R., Swinnen J.V. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr Rev. 12:1991;218-234
10. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 46:1994;399-405
11. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 16:1995;370-389
12. Manganiello V.C., Murata T., Taira M., Belfrage P., Degerman E. Perspectives in biochemistry and biophysics viversity in cyclic nucleotide phosphodiesterase isoenzyme families. Ar Biochem Biophys. 322:1995;1-13
13. Tanaka T., Hidaka H. Hydrophobic regions function in calmodulin-enzyme(s) interactions. J Biol Chem. 225:1980;11078-11080
14. Weishaar R.E., Kobylarz-Singer D.C., Steffen R.P., Kaplan H.R. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 61:1987;539-547
15. Sharma R.K. Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry. 30:1991;5963-5968
16. Harrison S.A., Reifsenyder D.H., Gallis B., Cadd G.G., Beavo J.A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol. 29:1986;506-514
17. Smith C.J., He J., Ricketts S.G., Ding J.Z., Moggio R.A., Hintze T.H. Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. Cell Biochem Biophys. 29:1998;67-88
18. Farah A.E., Alousi A.A. New cardiotonic agents: a search for digitalis substitute. Life Sci. 22:1978;1139-1148
19. Meacci E., Taira M., Moos M. Jr, Smith C.J., Movsesian M.A., Degerman E., et al. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 89:1992;3721-3725
20. Taira M., Hockman S.C., Calvo J.C., Taira M., Belfrage P., Manganiello V.C. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem. 268:1999;18573-18579
21. Reinhardt R.R., Chin E., Zhou J., Taira M., Murata T., Manganiello V.C., et al. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest. 95:1995;1528-1538
22. Okruhlicova L., Tribulova N., Styk J., Eckly A., Lugnier C., Slezk J. Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study. Mol Cell Biochem. 173:1997;183-188
23. Smith C.J., Huang R., Sun D., Ricketts S., Hoegler C., Ding J.Z., et al. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation. 96:1997;3116-3123
24. Picq M., Dubois M., Grynberg A., Lagarde M., Prigent A.F. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 28:1996;2151-2161
25. Jasmin G., Eu H.Y. Cardiomyopathy of hamster dostrophy. Ann NY Acad Sci. 317:1979;46-58
26. Bajusz E., Homburber F., Baker J.R., Opie L.H. The heart muscle in muscular dystrophy with special reference to involvement of the cardiovascular system in the hereditary myopathy of the hamster. Ann NY Acad Sci. 138:1966;213-231
27. Gertz E.W. Cardiomyopathic Syrian hamster: a possible model of human descase. Prog Exp Tumor Res. 16:1972;242-260
28. Lossnitzer K., Janke J., Hein B., Stauch M., Fleckenstein A. Disturbed myocardial calcium metabolism: a possible pathogenetic factor in the hereditary cardiomyopathy of the Syrian hamster. Recent Adv Stud Card Struct Metab. 6:1975;207-217
29. Jasmin G., Proschek L. Calcium and myocardial cell injury. An appraisal in the cardiomyopathic hamster. Can J Physiol Pharmacol. 62:1984;891-898
30. Wrogemann K., Nylen E.G. Mitochondrial calcium overloading in cardiomyopathic hamsters. J Mol Cell Cardiol. 10:1978;185-195
31. Panagia V., Singh J.N., Anand-Srivastava M.B., Pierce G.N., Jasmin G., Dhalla N.S. Sarcolemmal alterations during the development of genetically determined cardiomyopathy. Cardiovasc Res. 18:1984;567-572
32. 2+ exchange during the development of genetically determined cardiomyopathy. Biochem Biophys Res Commun. 133:1985;491-497
33. Hidaka H., Asano M., Iwadare S., Matsumoto I., Totsuka T., Aoki N. A novel vascular relaxing agent, N-(6-aminohexyl)-5-chloro-1- naphthalenesulfonamide which affects vascular smooth muscle actomyosin. J Pharmacol Exp Ther. 207:1978;8-15
34. Alousi A.A., Farah A.E., Lesher G.Y., Opalka C.J. Jr. Cardiotonic activity of amrinone-win 40680 [5-amino-3,4′-bipyridin-6(1H)-one]. Circ Res. 45:1979;666-677
35. Hidaka H., Hartshorne D.J. Calmodulin antagonists and cellular physiology. 1985;Academic Press Inc, New York
36. Satake N., Zhou Q., Morikawa M., Inoue M., Shibata S. Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase. J Cardiovasc Pharmacol. 25:1995;489-494
37. Sanada S., Kitakaze M., Papst P.J., Asanuma H., Node K., Takashima S., et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation. 104:2001;705-710
38. Hidaka H., Shibuya M. A new assay of cyclic nucleotide phosphodiesterase: its application to human serum. Biochem Med. 10:1974;301-311
39. Hidaka H., Sasaki Y., Tanaka T., Endo T., Ohno S., Fujii Y., et al. N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc Natl Acad Sci USA. 78:1981;4354-4357
40. Lowry O.H., Rosebrough N., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275
41. Maurice J.P., Shah A.S., Kypson A.P., Hata J.A., White D.C., Glower D.D., et al. β-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol. 276:1999;H1853-H1860
42. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and β-adrenergic- receptor density in failing human hearts. New Engl Med. 307:1982;205-211
43. Feldman A.M., Cates A.E., Veazey W.B., Hershberger R.E., Bristow M.R., Baughman K.L., et al. Increase of the 40000-mol wt pertussis toxin substrate (Gprotein) in the failing human heart. J Clin Invest. 82:1998;189-197
44. Clemson B., Gaul L., Gubin S.S., Campsey D.M., McConville J., Nussberger J., et al. Prejunctional angiotensin II receptors. J Clin Invest. 93:1994;684-691
45. Yoshida H., Takahashi M., Tanonaka K., Maki T., Nasa Y., Takeo S. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol. 134:2001;150-160
46. Spinale F.G., Holzgrefe H.H., Mukherjee R., Webb M.L., Hird R.B., Cavallo M.J., et al. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes. J Pharmacol Exp Ther. 283:1997;1082-1094
47. Volpi M., Sha'afi R.I., Epstein P.M., Andrenyak D.M., Feinstein M.B. Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin. Proc Natl Acad Sci USA. 78:1981;795-799
48. Sakamoto A. Electrical and ionic abnormalities in the heart of cardiomyopathic hamsters: in quest of a new paradigm for cardiac failure and lethal arrhythmia. Mol Cell Biochem. 259:2004;183-187
49. Lee H.C., Cai J.J., Yu H. Effect of protein kinase C on cyclic 3′,5′-adenosine monophosphate-dependent phosphodiesterase in hypertrophic cardiomyopathic hamster hearts. J Pharmacol Exp Therap. 270:1994;1171-1176
50. Cai J.J., Lee H.C. Protein kinase C isozyme-specific modulation of cyclic AMP-dependent phosphodiesterase in hypertrophic cardiomyopathic hamster hearts. Mol Pharmacol. 49:1996;81-88
51. Yu H., Cai J.J., Lee H.C. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts. Mol Pharmacol. 50:1996;549-555
52. Klamut H.J., Lin C.H., Strickland K.P. Calmodulin content and Ca-activated protease activity in dystrophic hamster muscles. Muscle Nerve. 6:1983;436-441
53. Moore P.B. UM-X71 myopathic hamster heart shows altered calcimedin protein levels. Biochem Biophys Res Commun. 121:1984;915-921
54. Mano T., Iwase K., Sawai Y., Oda N., Nishida Y., Mokuno T., et al. Changes of calmodulin concentration and cyclic 3′,5′-nucleotide phosphodiesterase activities in cardiac muscle of hyper- and hypothyroid rat. J Endocrinol. 143:1994;515-520